MKC-963

MKC-963 is an orally active and potent inhibitor targeting platelet aggregation-related pathways. MKC-963 exerts antithrombotic activity by inhibiting platelet aggregation, and can also induce autoinduction, i.e., upregulating the mRNA expression and activity of CYP3A4 enzyme to accelerate its own metabolism in vivo. MKC-963 is promising for research of platelet aggregation-related diseases (e.g., thrombosis) [1].

149549-14-4

12352005

Platelet-activating Factor Receptor (PAFR)

GPCR/G Protein

Neuroscience-Neuromodulation

Cardiovascular Disease

C[C@@H](NC1=NN=C(C2=CC=CC=C2)C3=C1C=CC=C3)C4CCCCC4

C22H25N3

331.45

[1]Shimizu T, et al. Autoinduction of MKC-963 [ (R) -1- (1-cyclohexylethylamino) -4-phenylphthalazine] metabolism in healthy volunteers and its retrospective evaluation using primary human hepatocytes and cDNA-expressed enzymes[J]. Drug metabolism and disposition, 2006, 34 (6) : 950-954.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19184/

Reference compound1

No Development Reported